336 Index Name Paper ref. Name Paper ref. Heinrich, A W19.2 Heishman, S FC14.3.4 Heitman, L Wed 058 Heliopoulos, I Mon 187 Helldén, A W35.4, Tue 308, Wed 147 Hellmann, M Wed 208 Hellstrom-Westas, L FC10.4.4, Wed 006, Thu 008 Helms, P Wed 137 Helms, PJ Tue 109 Heltovics, G Tue 130 Helyes, Z W19.3, FC16.2.6, Mon 318, Tue 250, Tue 271 Hempel, G FC10.4.5 Hendrich, J FC03.2.4 Heneka, M T FC18.3.3 Hennessy, M Thu 442 Henningsen, K Wed 433, Wed 397 Henningsson, A FC07.4.4 Henriksen, F Mon 061 Henriksen, K W26.4, W26.2 Henriksen, T Mon 406 Henríquez-Hernández, L Tue 387 Henthorn, T Mon 053 Heo, DK Mon 062 Hepburn, C Mon 211 Heras, M YI.03 Herber, O Tue 108 Hercberg, S Mon 145, Mon 132 Herdeiro, MT Thu 119, Tue 086, Mon 146 Herings, R FC04.1.6 Herman, Arnold G FC16.4.3 Hermann, M Tue 490 Hermans, JJR Mon 212 Hermenegildo, C Thu 225 Hernandes, MZ Thu 374 Hernandez Casaña, P Wed 344 Hernández, M Thu 249, Tue 213, Mon 411 Hernández, MC Tue 394 Hernandez, MT Wed 352 Hernandez-Balmaseda, I Wed 344 Hernandez-Cañero, A Mon 207 Hernández-Guijo, J FC16.2.5 Herrera Henriquez, MA Thu 330 Herrera, MD Tue 118 Herrera, E Tue 387 Hervera, A Thu 042, Wed 059 Hesse, B Wed 395 Heurteaux, C FC17.2.5, Thu 237 Heusler, P Mon 084 Hewett, P Mon 102 Heydari, A Tue 231, Heymes, C Wed 196 Hibbins, A Tue 456 Hibino, H Tue 147 Hibino, Y Wed 266, Thu 227 Hidaka, A Tue 266 Hieke, B Wed 234 Higa, T Mon 399 Higgins, P FC15.1.6 Higuchi, H Tue 140 Higuchi, H Wed 060 Higuchi, M Mon 213 Higuchi, Y Tue 413 Hikumwah, G Thu 315 Hilber, K Mon 218, Mon 217 Hildebrand, M FC03.2.1 Hildebrandt, W Tue 462 Hill, SR FC10.2.2, W36.1, W36.2 Hiller, S Thu 098 Hilmer, S FC13.2.6, FC13.1.6, Mon 392, Tue 309, Wed 125, Wed 126 Hintze, TH FC15.1.3 Hinz, B Tue 310, Thu 337 Hippisley-Cox, J FC04.1.6 Hippius, M Wed 119, Tue 131 Hirabara, Y Wed 223 Hirabayashi, N Tue 459 Hirafuji, M Mon 309, Thu 201 Hirai, K Thu 261 Hiramoto, T Tue 377 Hirano, M Mon 309 Hirao, A Mon 173, Tue 122 Hirasawa, A Tue 311, Wed 064 Hirata, M Thu 038 Hirayama, Y Mon 313 Hirayasu, Y Wed 422, Wed 415 Hirokane, G Wed 414 Hirose, S Thu 108 Hiroshi, K Thu 375 Hirota, Y Tue 168 Hirshman, MF FC05.2.6 Hirvonen, J Thu 170, Tue 032 Hisa, H Thu 263 Hisayuki, O Thu 213 Hishinuma, S Mon 178, Wed 061 Hjelvang, B FC13.3.6, Mon 118, Mon 406 Hjelvang, BR Mon 119 Hnasko, T FC02.2.4 Ho, EYW Thu 255 Ho, HP Thu 381 Ho, HR Mon 327 Ho, WSV Wed 260, Tue 471 Ho, W-Y Tue 146 Ho, Y-C Wed 035 Hoang, T Tue 396 Hobara, N Mon 174, Mon 306, Tue 154, Tue 415 Hocaoglu, N Mon 474, Tue 366, Tue 449, Tue 450, Hoch, M Tue 312 Hochi, H Wed 278 Hochstrasser, D Tue 166 Hodková, A Mon 409 Hodler, C Wed 443 Hoecherl, K Wed 234 Hoeck, Hans C W26.5 Hoedemaker, F Thu 315 Hoehn, T Thu 272 Hoever, P Tue 312 Hoffmann, C W01.1.4 Hofmann, F Wed 234 Hofmann, KP FC11.1.3 Hofstetter, A Mon 245 Høg, S FC11.5.6 Hogaboam, CM Mon 314 Hogan, P FC12.5.4 Högberg, C Wed 052
Name Paper ref. Name Paper ref. Högberg, Carl Wed 062 Högestätt, E FC09.4.5 Højgaard, L W24.4 Hokkanen, J Thu 348 Holanda, IR Tue 282 Holcberg, G Mon 054 Holgate, J FC14.3.5, FC14.2.3 Holicka, M Tue 240 Holler, M Mon 479, Tue 099 Holloway, K FC01.1.4 Holm, K Mon 328 Holm, L W35.4 Holst, B FC11.5.4, Thu 036 Holt, S Tue 314, Tue 313, Tue 131 Höltke, C Wed 037 Høltzermann, M Thu 405, Thu 404 Holý, A Tue 300 Home, P FC05.4.2 Homma, M Tue 315 Homma, N Wed 105 Hommers, L Wed 026 Hompesch, M Mon 175 Honda, K Tue 201, Wed 223, Wed 256, Thu 108, Thu 117, Thu 213, Thu 224 Hong, E Mon 176 Hong, T Wed 267 Hong, Zhou Wed 363 Hongprasong, N Thu 357 Honkalammi, J Tue 316 Honore, B Wed 240 Hooiveld, G Thu 438 Hopfgartner, G Tue 166 Hoppu, K FC10.3.1 Hoppu, Kalle FC10.2.1 Horikawa, K Thu 416 Horinouchi, T Mon 399 Horinouchi, Y Wed 247 Horiuchi, M Mon 439 Horiuchi, S Tue 459 Hornbak, M Thu 053 Horne, J Wed 261 Horner, B Thu 394 Horrillo, I Thu 031 Horsdal, HT FC04.2.7 Horsmans, Y FC04.2.6, Mon 141 Horvath, A Wed 185 Horváth, C Tue 078 Hosoda, M Tue 154 Hosoda, T Mon 178 Hosohata, K Tue 156 Hossain, MA Wed 080 Hosseini, R Tue 015 Hosseinzadeh, H Wed 364 Høst, C Mon 320 Hosten, N Tue 041 Hostettmann, K Wed 375 Hotchkiss, C Wed 150 Hotershall, J FC03.1.5 Hothersall, J Mon 275 Hou, H Mon 458 Hou, L Tue 033 Hou, N Mon 186 Hou, Qi Mon 310 Houze, P Wed 191 Hovatta, O W21.3 Howell, R Mon 265 Howlett, A Tue 145, Wed 029 Howng, S-L Mon 319 Hrabinova, M Tue 448 Hracsko, Z Mon 460 Hracskó, Z W19.2 Hristov, M Thu 240 Hristovski, D Thu 293 Hsiao, M-C Wed 430 Hsiao, WLW Thu 296 Hsieh, H-L Mon 311, Tue 293 Hsieh, W-K Wed 192 Hsu, C Wed 439 Hsu, H-Y Wed 106 Hsu, M-J Mon 423 Hsu, S-P Wed 449 Hsu, T Mon 158 Hsu, Y-H Thu 362 Hu, C-B Mon 158 Hu, J Thu 372, Mon 323 Hu, J-J Mon 421, Wed 346 Hu, L Wed 242 Hu, M FC02.4.6, Tue 139, Tue 140 Hu, X Mon 349, Mon 032 Hu, Y Mon 466, Mon 445, Thu 300 Hu, Z Tue 076 Hua, Y Tue 158 Huabprasert, S Thu 361 Huala, I Tue 326 Huang, C Wed 365, Wed 366 Huang, C-Y Mon 158 Huang, F Tue 365 Huang, HC Mon 356 Huang, J-H Thu 287, Thu 288 Huang, J-L Tue 082 Huang, O Tue 317 Huang, OP Tue 036 Huang, P FC18.4.1 Huang, P-T Tue 083 Huang, Q Tue 158, Wed 258 Huang, Q-R Wed 291 Huang, S-C Wed 262 Huang, T Wed 076 Huang, W-T Mon 270 Huang, X Thu 044 Huang, X-N Tue 184, Tue 178 Huang, Y FC07.2.5, FC15.3.2, FC15.4.7 Huang, Y-W Mon 158 Huang, Z-M Wed 367 Huang, Z-N Tue 382 Hüpkes, M Mon 463 Hüting, D Mon 245 Hütter, J Thu 091 Hugar, S Thu 333 Hughes, AD Thu 069, Thu 259 Hughes, IE PL18 Hughes, KH Thu 207 Huh, W Tue 335 Huhtinen, A Thu 084 Huizer-Pajkos, A FC13.2.6 Hum, M Tue 414 Index 337
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289: FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor